JD Health International Inc. disclosed a minor change in its capital structure following the issuance of 300,000 ordinary shares on 4 June 2026 under its Post-IPO Share Award Scheme. The new issue expanded the company’s outstanding share base by 0.009 %, taking the total to 3.21 billion shares as of 5 June 2026.

In parallel, the healthcare platform continued its share-repurchase programme. Between 15 May and 5 June 2026, JD Health bought back 16.17 million shares for cancellation, equal to 0.505 % of the share capital authorised in its June 2025 mandate. The most recent on-market repurchase on 5 June amounted to 225,400 shares at prices ranging from HK$37.62 to HK$37.80, for a total consideration of HK$8.50 million.

The repurchased shares have yet to be cancelled, and the company remains within the authorised limit of 320.01 million shares under the current buyback mandate. A 30-day moratorium on new share issues or treasury-share sales runs through 5 July 2026 following the latest repurchase activity.